$6.99
2.34% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US03475V1017
Symbol
ANGO

AngioDynamics, Inc. Stock price

$6.99
+0.26 3.86% 1M
+0.82 13.29% 6M
-0.85 10.84% YTD
+0.24 3.56% 1Y
-21.86 75.77% 3Y
-8.63 55.25% 5Y
-10.26 59.48% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.16 2.34%
ISIN
US03475V1017
Symbol
ANGO
Sector

Key metrics

Market capitalization $284.03m
Enterprise Value $234.44m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.80
P/S ratio (TTM) P/S ratio 0.97
P/B ratio (TTM) P/B ratio 1.46
Revenue growth (TTM) Revenue growth -12.85%
Revenue (TTM) Revenue $292.73m
EBIT (operating result TTM) EBIT $-32.83m
Free Cash Flow (TTM) Free Cash Flow $-29.66m
Cash position $55.01m
EPS (TTM) EPS $-6.04
P/E forward negative
P/S forward 1.00
EV/Sales forward 0.83
Short interest 3.69%
Show more

Is AngioDynamics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

AngioDynamics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a AngioDynamics, Inc. forecast:

3x Buy
100%

Analyst Opinions

3 Analysts have issued a AngioDynamics, Inc. forecast:

Buy
100%

Financial data from AngioDynamics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Aug '24
+/-
%
293 293
13% 13%
100%
- Direct Costs 153 153
15% 15%
52%
139 139
10% 10%
48%
- Selling and Administrative Expenses 115 115
1% 1%
39%
- Research and Development Expense 30 30
1% 1%
10%
-5.02 -5.02
144% 144%
-2%
- Depreciation and Amortization 28 28
14% 14%
10%
EBIT (Operating Income) EBIT -33 -33
57% 57%
-11%
Net Profit -243 -243
3,868% 3,868%
-83%

In millions USD.

Don't miss a Thing! We will send you all news about AngioDynamics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AngioDynamics, Inc. Stock News

Neutral
Business Wire
about one month ago
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced the launch of an international multi-center prospective registry study to assess the long term effects of treatin...
Neutral
Business Wire
about one month ago
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that IRE has received CPT® Category I codes for the treatment of lesions in the prostate and liver. The decision ...
Negative
The Motley Fool
about 2 months ago
Investors didn't like the medical technology company's fiscal 2025 Q1 update.
More AngioDynamics, Inc. News

Company Profile

AngioDynamics, Inc. engages in the development, manufacture, and sale of medical devices for vascular access, surgery, peripheral vascular disease, and oncology. It offers ablation systems, fluid management systems, vascular access, angiographic, drainage. thrombolytic, and venous products. The company was founded by Eamonn P. Hobbs in 1988 and is headquartered in Latham, NY.

Head office United States
CEO James Clemmer
Employees 748
Founded 1988
Website www.angiodynamics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today